Showing results (201-210 of 297) with videos related to

Sort By:
Pageof 30
JAMA Oncology|February 29, 2024
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJoanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, et al.
NPJ Breast Cancer|June 25, 2026
Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriersMartin Widschwendter, Rita Schmutzler, Nora Pashayan, et al.
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.
Breast Cancer Research and Treatment|August 21, 2013
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerAllan Lipton, Laurie Goodman, Kim Leitzel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 29, 2011
Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen, Sean Brummel, Yuan Chun Ding, et al.
JAMA Oncology|February 29, 2024
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJan Lubinski, Joanne Kotsopoulos, Pal Moller, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Cancer Research|July 9, 2009
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriersTimothy R Rebbeck, Nandita Mitra, Susan M Domchek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast CancerSherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Pageof 30